Published in Eur J Clin Pharmacol on February 02, 2010
Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion. Theranostics (2015) 0.82
Erythropoiesis stimulating agents: approaches to modulate activity. Biologics (2013) 0.80
Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents. CPT Pharmacometrics Syst Pharmacol (2013) 0.77
Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats. Clin Exp Nephrol (2012) 0.77
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis. Biologics (2013) 0.76
Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem (1996) 4.72
Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A (1985) 3.28
Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood (2005) 3.10
Purification of human erythropoietin. J Biol Chem (1977) 2.83
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest (2007) 2.39
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol (1999) 2.29
Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development (1999) 2.00
Biosimilar therapeutics-what do we need to consider? NDT Plus (2009) 1.99
Erythropoietins: a common mechanism of action. Exp Hematol (2008) 1.89
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood (2010) 1.84
Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer (2001) 1.72
Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem (2002) 1.70
Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci (2005) 1.61
Humoral regulation of red cell production. Blood (1953) 1.60
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol (2003) 1.57
Structural characterization of human erythropoietin. J Biol Chem (1986) 1.54
Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant (2005) 1.52
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol (2006) 1.52
Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol (2003) 1.51
Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood (2002) 1.44
Red blood cell mass and plasma volume changes in manned space flight. JAMA (1967) 1.41
Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol (2004) 1.40
Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant (2001) 1.40
Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem (2005) 1.29
The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol (2008) 1.26
Mapping of the active site of recombinant human erythropoietin. Blood (1997) 1.25
Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant (2002) 1.24
Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry (1992) 1.16
Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int (2007) 1.12
Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int (2007) 1.10
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol (2006) 1.08
Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer (2007) 1.08
Pathobiology of heme interaction with the erythrocyte membrane. Semin Hematol (1989) 1.07
Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry (1987) 1.07
Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells (2006) 1.05
Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology (2007) 1.05
Antioxidative effects of erythropoietin. Kidney Int Suppl (2007) 1.03
Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep (2003) 1.02
Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol (2005) 1.00
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer (2005) 1.00
Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods (2009) 0.99
Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci (2009) 0.96
Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin. J Biol Chem (2004) 0.96
Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer (2008) 0.94
Regulation of erythrocyte lifespan: do reactive oxygen species set the clock? J Clin Invest (2007) 0.93
Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther (2002) 0.93
Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw (2008) 0.89
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci (2009) 0.88
Activation of erythropoietin signaling by receptor dimerization. Int J Biochem Cell Biol (1999) 0.86
Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol (2005) 0.86
Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol (2007) 0.84
Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha. Br J Haematol (2003) 0.83
Implications of neocytolysis for optimal management of anaemia in chronic kidney disease. Nephron Clin Pract (2007) 0.83
Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant (2009) 0.82
Preliminary clinical report of the medical aspects of Apollos VII and 8. Aerosp Med (1969) 0.79
Erythropoietin receptor in ovarian cancer cells - Letter. Mol Cancer Ther (2010) 0.77
The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant (2006) 0.76
Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Acta Haematol (2005) 0.76
Effects of hyperoxia on red blood cell survival in the normal rat. Aerosp Med (1970) 0.75
The effect of frequent or occasional dialysis-associated hypotension on survival of patients on maintenance haemodialysis. Nephrol Dial Transplant (2003) 1.90
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood (2010) 1.84
Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension (2006) 1.53
Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford) (2009) 1.52
The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrol Dial Transplant (2004) 1.51
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Lower retinol levels as an independent predictor of mortality in long-term hemodialysis patients: a prospective observational cohort study. Am J Kidney Dis (2010) 1.43
Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 1.41
Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol (2007) 1.38
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res (2006) 1.31
Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis (2006) 1.31
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther (2004) 1.28
Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery (2002) 1.27
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther (2011) 1.24
Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology (2008) 1.15
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res (2012) 1.14
Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor subtype 1A knockout mice. J Hypertens (2008) 1.11
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer (2010) 1.08
Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol (2003) 1.08
AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens (2006) 1.07
Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. J Pharmacol Exp Ther (2009) 1.05
Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res (2005) 1.05
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol (2004) 1.04
Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem (2003) 1.03
Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant (2007) 1.03
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol (2006) 1.02
Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol (2010) 1.01
Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int J Oncol (2007) 0.98
The robotic approach to complex hepatobiliary anomalies in children: preliminary report. J Pediatr Surg (2007) 0.97
A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients. Ann N Y Acad Sci (2007) 0.95
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep (2011) 0.95
Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Mol Carcinog (2012) 0.94
Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol (2007) 0.93
AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res (2006) 0.93
Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci Rep (2012) 0.90
Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension. Kidney Blood Press Res (2002) 0.90
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem (2010) 0.86
The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res (2007) 0.86
Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Exp Cell Res (2011) 0.86
Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. Int J Oncol (2013) 0.86
Circulating endothelial progenitor cells in patients with ANCA-associated vasculitis. Kidney Blood Press Res (2008) 0.86
Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway. Toxicol Lett (2005) 0.85
Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents. Clin Pharmacokinet (2013) 0.84
MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS One (2013) 0.84
Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery (2004) 0.84
Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat (2014) 0.84
Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. J Hypertens (2010) 0.84
Chlorine dioxide is a size-selective antimicrobial agent. PLoS One (2013) 0.84
Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant (2003) 0.83
Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase. Am J Cancer Res (2012) 0.82
Glyceollin I enantiomers distinctly regulate ER-mediated gene expression. Steroids (2010) 0.82
Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis? Kidney Blood Press Res (2006) 0.81
Influence of the endothelial nitric oxide synthase polymorphism on the progression of autosomal dominant polycystic kidney disease and IgA nephropathy. Ren Fail (2002) 0.81
Oxidative stress and platelet function in multiple myeloma and renal insufficiency: clinical relations of different tests. Thromb Res (2002) 0.80
Endothelin receptor blockade does not affect blood pressure or angiotensin II levels in CYP1A1-Ren-2 transgenic rats with acutely induced hypertension. Vascul Pharmacol (2009) 0.80
Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul Pharmacol (2008) 0.80
Antiphospholipid antibodies in patients with lupus nephritis. Ren Fail (2003) 0.79
Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. J Endocrinol (2012) 0.79
microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Mol Cancer (2014) 0.79
Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int Suppl (2003) 0.79
Estrogenic and antiestrogenic activities of phytoalexins from red kidney bean (Phaseolus vulgaris L.). J Agric Food Chem (2010) 0.79
Age-dependent parathormone levels and different CKD-MBD treatment practices of dialysis patients in Hungary--results from a nationwide clinical audit. BMC Nephrol (2013) 0.78
Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol (2012) 0.78
Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit (2005) 0.78
Resting energy expenditure and thermal balance during isothermic and thermoneutral haemodialysis--heat production does not explain increased body temperature during haemodialysis. Nephrol Dial Transplant (2007) 0.78
Advanced glycation end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio. Ren Fail (2003) 0.77
Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats. Kidney Blood Press Res (2004) 0.77
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. Kidney Blood Press Res (2010) 0.77
Plasma calprotectin in chronically dialyzed end-stage renal disease patients. Inflamm Res (2009) 0.77
Chemotherapy-induced anemia: the story of darbepoetin alfa. Curr Med Res Opin (2013) 0.77
Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Acta Haematol (2005) 0.76
Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Dis Markers (2009) 0.76
Effect of hemodiafiltration on pregnancy-associated plasma protein A (PAPP-A) and related parameters. Ren Fail (2006) 0.75
Monocyte 'reprogramming' and mortality in septic patients with acute kidney injury. Blood Purif (2008) 0.75
Anterior fundoplication at the time of congenital diaphragmatic hernia repair. Pediatr Surg Int (2009) 0.75
Interaction between angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on survival in hemodialyzed patients. Medicine (Baltimore) (2014) 0.75
Immunotactoid glomerulonephritis as a cause of acute renal failure. Nephrol Dial Transplant (2004) 0.75
[Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function]. Orv Hetil (2008) 0.75
Changes in levels of matrix metalloproteinase-2 and -9, pregnancy-associated plasma protein-A in patients with various nephropathies. J Nephrol (2012) 0.75
Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease. Clin Lab (2012) 0.75